Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).
-- "ADX-324, A Semi-Annual SC Investigational siRNA Targeting Prekallikrein for HAE Attack Prevention" (Poster number: 089) on Friday, February 27, 2026 from 2:45 -- 3:45 pm EST in the Pennsylvania ...
A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...
Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 –– Positive ...
Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer to further strengthen cardiovascular portfolio and enter dynamic field of ...
A randomized, clinical trial testing vutrisiran, a small-interfering RNA (siRNA) therapy for the treatment of cardiomyopathy resulting from transthyretin amyloidosis (ATTR-CM), has met its primary ...
New findings point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer. In everyday life, when things turn out ...
Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.
Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results